Weighing the Risks: the Management of Bipolar Disorder During Pregnancy
Purpose of Review
The management of bipolar disorder during pregnancy requires difficult treatment decisions be made by both women and their clinicians. There is little consensus on management despite the high prevalence of bipolar disorder in reproductive-aged women. In this review, we have summarized the available literature and discuss the balancing of risks associated with treatment decisions.
Cohort studies have shown a high relapse rate in women with bipolar disorder who discontinue mood-stabilizing medications. The risks of fetal medication exposure have been assessed in multiple database studies.
Management decisions of bipolar disorder in pregnancy have been made difficult by inconsistencies in study outcomes. There were many confounding factors in the studies of medication discontinuation relapse risk. Inconsistencies in the findings of fetal risks from mood-stabilizing medications have further complicated management decisions. Larger studies are needed to clarify the risks of bipolar disorder relapse in pregnancy with and without treatment.
KeywordsPeripartum Antenatal Depression Bipolar disorder Psychopharmacology Pregnancy
Compliance with Ethical Standards
Conflict of Interest
Michael Thomson declares no conflict of interest.
Verinder Sharma reports grants from Assurex, Genome Canada, Neurocrine Biosciences, Sage Therapeutics, Stanley Medical Research Institute and Sunovion Pharmaceuticals outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.Sit D. Women and bipolar disorder across the life span. J Am Med Womens Assoc. 2004;59(2):91–100.Google Scholar
- 3.Boden R, Lundgren M, Brandt L, Reutfors J, Andersen M, Kieler H. Risks of adverse pregnancy and birth outcomes in women treated or not treated with mood stabilisers for bipolar disorder: population based cohort study. BMJ. 2012;345(nov07 6):e7085. https://doi.org/10.1136/bmj.e7085.CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Sharma V, Sharma S. Peripartum management of bipolar disorder: what do the latest guidelines recommend? Expert Rev Neurother. 2016;17:1–10.Google Scholar
- 5.• Wesseloo R, Liu X, Clark CT, Kushner SA, Munk-Olsen T, Bergink V. Risk of postpartum episodes in women with bipolar disorder after lamotrigine or lithium use during pregnancy: a population-based cohort study. J Affect Disord. 2017;218:394–7. This study showed comparable rates of postpartum bipolar disorder relapses following lamotrigine or lithium use during pregnancy.CrossRefPubMedGoogle Scholar
- 6.Viguera AC, Whitfield T, Baldessarini RJ, Newport DJ, Stowe Z, Reminick A, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry. 2007;164(12):1817–24: quiz 923. https://doi.org/10.1176/appi.ajp.2007.06101639.CrossRefPubMedGoogle Scholar
- 9.Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64(5):543–52. https://doi.org/10.1001/archpsyc.64.5.543.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Ban L, Fleming KM, Doyle P, Smeeth L, Hubbard RB, Fiaschi L, et al. Congenital anomalies in children of mothers taking antiepileptic drugs with and without periconceptional high dose folic acid use: a population-based cohort study. PLoS One. 2015;10(7):e0131130. https://doi.org/10.1371/journal.pone.0131130.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Sadowski A, Todorow M, Yazdani Brojeni P, Koren G, Nulman I. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: a cohort study. BMJ Open. 2013;3(7):e003062. https://doi.org/10.1136/bmjopen-2013-003062.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1–44. https://doi.org/10.1111/bdi.12025.CrossRefPubMedGoogle Scholar
- 32.Mazza M, Mandelli L, Di Nicola M, Harnic D, Catalano V, Tedeschi D, et al. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up. J Affect Disord. 2009;115(1–2):27–35. https://doi.org/10.1016/j.jad.2008.08.019.CrossRefPubMedGoogle Scholar
- 36.•• Wesseloo R, Kamperman AM, Munk-Olsen T, Pop VJ, Kushner SA, Bergink V. Risk of postpartum relapse in bipolar disorder and postpartum psychosis: a systematic review and meta-analysis. Am J Psychiatry. 2016;173(2):117–27. This recent meta-analysis shows the high rate of postpartum relapse that occurs in women with bipolar disorder. In this study, women who continuned maintenance medications or started prophylactic medications immediately following childbirth had a much lower relapse rate than women who remained medication-free.CrossRefPubMedGoogle Scholar
- 37.Veroniki AA, Rios P, Cogo E, Straus SE, Finkelstein Y, Kealey R, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open. 2017;7(7):e017248. https://doi.org/10.1136/bmjopen-2017-017248.CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Rasmussen MH, Strom M, Wohlfahrt J, Videbech P, Melbye M. Risk, treatment duration, and recurrence risk of postpartum affective disorder in women with no prior psychiatric history: a population-based cohort study. PLoS Med. 2017;14(9):e1002392. https://doi.org/10.1371/journal.pmed.1002392.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.National Institute for Health and Excellence Care. Antenatal and postnatal mental health 2016 https://www.nice.org.uk/guidance/qs115/resources/antenatal-and-postnatal-mental-health-75545299789765. Accessed 23 Sep 2017.
- 45.• Patorno E, Huybrechts KF, Hernandez-Diaz S, et al. N Engl J Med. 2017;377:893–4. This large cohort study demonstrated an increased risk of cardiac defects following in utero lithium exposure. However, the rate of cardiac defects found in this study was much lower than that seen in previous studies.CrossRefPubMedGoogle Scholar
- 46.Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry. 2014;171(7):785–94. https://doi.org/10.1176/appi.ajp.2014.12111402.CrossRefPubMedGoogle Scholar
- 48.Holmes LB, Baldwin EJ, Smith CR, Habecker E, Glassman L, Wong SL, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology. 2008;70(22 Pt 2):2152–8. https://doi.org/10.1212/01.wnl.0000304343.45104.d6.CrossRefPubMedGoogle Scholar
- 50.Benoit R. Does lithium exposure warrant referral for fetal echocardiogram? Am J Obstet Gynecol. 2004;191(6):S127.Google Scholar
- 52.• Pariente G, Leibson T, Shulman T, Adams-Webber T, Barzilay E, Nulman I. Pregnancy outcomes following in utero exposure to lamotrigine: a systematic review and meta-analysis. CNS Drugs. 2017;31(6):439–50. This systematic review and meta-analysis summarizes the safety data for lamotrigine use in pregnancy.CrossRefPubMedGoogle Scholar
- 54.Dolk H, Jentink J, Loane M, Morris J, de Jong-van den Berg LT. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–22. https://doi.org/10.1212/01.wnl.0000316194.98475.d8.CrossRefPubMedGoogle Scholar